Fleischmann, R., Blanco Alonso, R., Van den Bosch, F., Bassette, L., Song, Y., Penn, S. K., . . . Mysler, E. (2024). Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-year data from SELECT-COMPARE.
Citación estilo ChicagoFleischmann, Roy, et al. Long-term Efficacy and Safety Following Switch between Upadacitinib and Adalimumab in Patients With Rheumatoid Arthritis: 5-year Data From SELECT-COMPARE. 2024.
Cita MLAFleischmann, Roy, et al. Long-term Efficacy and Safety Following Switch between Upadacitinib and Adalimumab in Patients With Rheumatoid Arthritis: 5-year Data From SELECT-COMPARE. 2024.
Precaución: Estas citas no son 100% exactas.